Litcius/Paper detail

Darbepoetin alfa to reduce transfusion episodes in infants with haemolytic disease of the fetus and newborn who are treated with intrauterine transfusions in the Netherlands: an open-label, single-centre, phase 2, randomised, controlled trial

Isabelle M. C. Ree, Masja de Haas, Nan van Geloven, Sandra E. Juul, Derek de Winter, E. J. T. Verweij, Dick Oepkes, Johanna G. van der Bom, Enrico Lopriore

2023The Lancet Haematology11 citationsDOIOpen Access PDF

Topics & Concepts

MedicineDarbepoetin alfaPediatricsPopulationObstetricsAnemiaInternal medicineEnvironmental healthBlood transfusion and managementBlood groups and transfusionNeonatal Health and Biochemistry
Darbepoetin alfa to reduce transfusion episodes in infants with haemolytic disease of the fetus and newborn who are treated with intrauterine transfusions in the Netherlands: an open-label, single-centre, phase 2, randomised, controlled trial | Litcius